HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Alemtuzumab for multiple sclerosis: who and when to treat?

AuthorsTill Sprenger, Ludwig Kappos
JournalLancet (London, England) (Lancet) Vol. 380 Issue 9856 Pg. 1795-7 (Nov 24 2012) ISSN: 1474-547X [Electronic] England
PMID23128041 (Publication Type: Journal Article, Comment)
Chemical References
  • Adjuvants, Immunologic
  • Antibodies, Monoclonal, Humanized
  • Immunosuppressive Agents
  • Peptides
  • Alemtuzumab
  • Glatiramer Acetate
  • Interferon-beta
  • Interferon beta-1a
Topics
  • Adjuvants, Immunologic (administration & dosage)
  • Alemtuzumab
  • Antibodies, Monoclonal, Humanized (administration & dosage)
  • Female
  • Glatiramer Acetate
  • Humans
  • Immunosuppressive Agents (administration & dosage)
  • Interferon beta-1a
  • Interferon-beta (administration & dosage)
  • Male
  • Multiple Sclerosis, Relapsing-Remitting (drug therapy)
  • Peptides (administration & dosage)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: